A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).

Jesus G. Berdeja; Tara K. Gregory; Jeffrey Matous; Lowell L. Hart; Rami Owera; Joseph Ronald Mace; James H. Essell; Ian Flinn; Edward Anthony Faber

doi:10.1200/JCO.2015.33.15_SUPPL.8513

A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).

Jesus G. Berdeja
, Tara K. Gregory
, Jeffrey Matous
, Lowell L. Hart
, Rami Owera
, Joseph Ronald Mace
, James H. Essell
, Ian Flinn
, Edward Anthony Faber

Sarah Cannon Research Institute
Colorado Blood Cancer Institute, Denver, CO
Florida Cancer Specialists, Fort Myers, FL
Woodlands Medical Specialists PA, Pensacola, FL
Florida Cancer Specialists, St Petersburg, FL
Oncology/Hematology Care, Inc, Cincinnati, OH

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	33
DOIs	https://doi.org/10.1200/JCO.2015.33.15_SUPPL.8513
State	Published - May 20 2015
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2015.33.15_SUPPL.8513License: Unspecified

Cite this

Berdeja, J. G., Gregory, T. K., Matous, J., Hart, L. L., Owera, R., Mace, J. R., Essell, J. H., Flinn, I., & Faber, E. A. (2015). A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM). Journal of Clinical Oncology, 33. https://doi.org/10.1200/JCO.2015.33.15_SUPPL.8513

@article{0fd662481fe24f39b98881eef8b3ef53,

title = "A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).",

author = "Berdeja, \{Jesus G.\} and Gregory, \{Tara K.\} and Jeffrey Matous and Hart, \{Lowell L.\} and Rami Owera and Mace, \{Joseph Ronald\} and Essell, \{James H.\} and Ian Flinn and Faber, \{Edward Anthony\}",

note = "8513 Background: Histone deacetylase inhibitors (HDACi) and proteasome inhibitors (PI) act synergistically through inhibition of the proteasome and aggresome pathways. We have previously reported the combination of the HDACi, PAN and the PI, CFZ in pts with relapsed and relapsed/refractory MM with encouraging results (Blood 2013;122:1937).",

year = "2015",

month = may,

day = "20",

doi = "10.1200/JCO.2015.33.15\_SUPPL.8513",

language = "American English",

volume = "33",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).

AU - Berdeja, Jesus G.

AU - Gregory, Tara K.

AU - Matous, Jeffrey

AU - Hart, Lowell L.

AU - Owera, Rami

AU - Mace, Joseph Ronald

AU - Essell, James H.

AU - Flinn, Ian

AU - Faber, Edward Anthony

N1 - 8513 Background: Histone deacetylase inhibitors (HDACi) and proteasome inhibitors (PI) act synergistically through inhibition of the proteasome and aggresome pathways. We have previously reported the combination of the HDACi, PAN and the PI, CFZ in pts with relapsed and relapsed/refractory MM with encouraging results (Blood 2013;122:1937).

PY - 2015/5/20

Y1 - 2015/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.8513

U2 - 10.1200/JCO.2015.33.15_SUPPL.8513

DO - 10.1200/JCO.2015.33.15_SUPPL.8513

M3 - Article

VL - 33

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).

Disciplines

Access to Document

Other files and links

Cite this